TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Chemosensitivity of fresh tumor samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Food acceptability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of mothers who exclusively breastfeed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Quality Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sign score on the treated area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subcutaneous fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: [11C]LY2795050 volume of distribution (VT) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The amount of blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitation of pimonidazole staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Neuropathic Pain Sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cold pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: acceptance rate of intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in nutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Re-presentation to hospital with suicide attempt and/or suicidal ideations
Endpoint domain: Adverse events/effects
Primary endpoint: Death by suicide rates
Endpoint domain: Mortality/survival
Primary endpoint: Long term survival
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of cortical lesions in the primary sensorimotor cortex (SM1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unimanual motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of E5501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing acute myelogenous leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Screening Adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Incident STI infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cardiac remodelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of maximal concentric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement induced pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure induced pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of multiple doses of PF-04171327
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters of PF-04171327 after multiple doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacodynamic effects on chemical and metabolic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of febrile events
Endpoint domain: Adverse events/effects
Primary endpoint: standard ocular examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measurement of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Are Abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Electrical Energy Delivered (TEED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with increased serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in cystometric bladder capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of repeated hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Duration of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Patients Initiating Specific Anticoagulant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Initiating Specific Anticoagulant Dose - Dabigatran
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Initiating Specific Anticoagulant Dose - Apixaban
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Initiating Specific Anticoagulant Dose - Rivaroxaban
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual analogue scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of peroxides in the urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transition from VAT to VAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants who initiate MOUD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Podocan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WNT regulatory molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sportcord Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Postoperative Numeric Rating Scale (NRS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Postoperative Numeric Rating Scale (NRS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total CD4 T cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of intravenous blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Cognitive Test Battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cmax of ONO-4538
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of ONO-4538
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC21day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in complete spontaneous bowel movements per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Brain-Derived Neurotrophic Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Interleukin-1 receptor agonist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Target Plaque Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Local Skin Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve of the analyte in plasma at steady state (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of the analyte in plasma at steady state (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with abnormal scar findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of dormant conduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the Apollo EE Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the Apollo EE Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in B natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of six minutes walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ocular deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate Verbal Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Delayed Verbal Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Verbal Memory Recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiorespiratory autonomic reflexes incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IGF-1 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completeness of Capsule Endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of women delivered before 37 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Change in expression of immune checkpoint biomarkers on circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: urea nitrogen of 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prealbumin(PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed concentration of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve from time zero extrapolated to infinity for rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ottawa Scale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Opiate abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response to MUC-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell response against MUC-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Enrollment in Medication Assisted Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lack of Treatment Response to Biological Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine for PGEm Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Acute GvHD Grades III-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With Grades 3-5 Non-hematologic Adverse Events Related to the T Cell Product
Endpoint domain: Adverse events/effects
Primary endpoint: Morphine Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive screening rate of Fabry Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of eosinophils (absolute cell count) in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of eosinophils (percentage count) in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Point prevalence of smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gestational age at delivery
Endpoint domain: Mortality/survival
Primary endpoint: Stress levels pre and post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in cytokine IL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative abundance of MET-4 associated bacterial strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence/absence of GERD as assessed by endoscopic Los Angeles (LA) grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dental health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arthralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical Benefit Response (CBR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood sample analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gene expression changes in the small airway epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal Infant Pain Scale (NIPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anesthetic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnosis accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Success of Spinal Labor Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total morphine used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of JX-594
Endpoint domain: Adverse events/effects
Primary endpoint: Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: burnout levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: post-trauma stress disorder levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measurement of area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Symptomatic CNS Hemorrhage Grade ≥2
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to identify and cannulate the duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Brain Resting State Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Weight loss or maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Jankovic rating scale (JRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of lower lid tear meniscus height (TMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of logins/month/participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: FSHD-COM validation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Timed Up and Go Test validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of nutritionally at risk patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes Scores on Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of treatment
Endpoint domain: Resource use
Primary endpoint: Incidence of deep-vein thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of non-fatal pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of major bleeding after first dose of rivaroxaban
Endpoint domain: Adverse events/effects
Primary endpoint: Death related to postoperative bleedings
Endpoint domain: Mortality/survival
Primary endpoint: Change in caregiver trauma symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Caregiver Parenting Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute pain by narcotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute pain by pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody Titers Against IgG and IgA Immunizing Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of patients develop postpartum hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Responders With a Reduction of Signs and Symptoms of Ankylosing Spondylitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative CD54 Upregulation Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of preeclampsia
Endpoint domain: Adverse events/effects
Primary endpoint: time needed to reach TOF ratio ≥ 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of acute skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Motor Subscale of Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) Normative Composite Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function Measure (GMFM-88) Total Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) Scaled Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Medication Refill Compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Paternity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sperm quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: True bed exit detections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False bed exit detections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Copenhagen Hip and Groin Outcome Score (HAGOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline of Erythrocyte Omega-3 Index %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse Event Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of parastomal hernia formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Tube-site pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain medication requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Surgical Site Infection (non-organ space)
Endpoint domain: Adverse events/effects
Primary endpoint: Functional MR Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-HT2A binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: obstetric or maternal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to time of last measurable concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (CMAX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes